Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis
- 1 December 1988
- journal article
- clinical trial
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 158 (2) , 233-236
- https://doi.org/10.1016/0002-9378(88)90128-7
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin)Fertility and Sterility, 1985
- Revised American Fertility Society Classification of Endometriosis: 1985Fertility and Sterility, 1985
- Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosisFertility and Sterility, 1984
- Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phaseFertility and Sterility, 1983
- Gonadotropin-Releasing Hormone Agonist Suppresses Ovulation, Menses, and Endometriosis in Monkeys: An Individualized, Intermittent Regimen*Journal of Clinical Endocrinology & Metabolism, 1983
- Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonistFertility and Sterility, 1982
- Endometriosis: Role of Ovarian Steroids in Initiation, Maintenance, and SuppressionFertility and Sterility, 1980